Peripheral T-or natural killer (NK)-cell lymphomas are rare and difficult-to-recognize diseases. It remains arduous to distinguish between NK cell-and cytotoxic T-lymphocyte-derived lymphomas through routine histological evaluation. To clarify the cells of origin, we focused on NK-cell receptors and examined the expression using immunohistochemistry in 22 cases with T-and NK-cell neoplasms comprising angioimmunoblastic T-cell lymphoma, anaplastic lymphoma kinase (ALK)-positive and -negative anaplastic large-cell lymphomas, extranodal NK/T-cell lymphoma, nasal type, monomorphic epitheliotropic intestinal T-cell lymphoma, aggressive NKcell leukemia, and other peripheral T-cell lymphomas. Inhibitory receptor leukocyte immunoglobulin-like receptor subfamily B member 1 (LILRB1) was detected in 14 (64%) cases, whereas activating receptors DNAM1, NKp46, and NKG2D were expressed in 7 (32%), 9 (41%), and 5 (23%) cases, respectively. Although LILRB1 was detected regardless of the disease entity, the activating NK-cell receptors were expressed predominantly in TIA-1-positive neoplasms (DNAM1, 49%; NKp46, 69%; and NKG2D, 38%). In addition, NKp46 and NKG2D were detected only in NK-cell neoplasms and cytotoxic T-lymphocyte-derived lymphomas including monomorphic epitheliotropic intestinal T-cell lymphoma. One Epstein-Barr virus-harboring cytotoxic T-lymphocyte-derived lymphoma mimicking extranodal NK/T-cell lymphoma, nasal type lacked these NK-cell receptors, indicating different cell origin from NK and innate-like T cells. Furthermore, NKG2D expression showed a negative impact on survival among the 22 examined cases, which mainly received the standard chemotherapy regimen (log-rank test, P = .024). We propose that the presence of activating NK-cell receptors may provide new insights into understanding peripheral T-cell lymphomas and characterizing them as innate-like T-cell neoplasm.
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| INTRODUCTION
Peripheral T-or NK-cell lymphomas are a group of rare diseases. 1 Although they account for 15%-20% of aggressive lymphomas in Western countries, 2 the number is higher in Japan, accounting for 30%-40% of aggressive lymphomas. 2, 3 The differences are explained by the high incidence of HTLV-I-associated ATLL and EBV-associated ENKL. 2, 3 Although the current WHO classification includes more than 25 disease entities in PTNKL, making a correct diagnosis per se has a prognostic impact on clinical outcome. 1, 2 With increased understanding of PTNKL, subtype-specific approaches have shown to achieve a promising therapeutic effect, particularly in ENKL. 4 Although ATLL is defined as the HTLV-I-harboring CD4 + T-cell neoplasm, ENKL is composed of EBV-harboring CM-positive neoplasms of different cell lineages including abT cells, cdT cells and NK cells. 1, 2, 5 Recent observation showed the existence of EBV-harboring CTL-type PTCL mimicking ENKL. 6 These cases raise concerns regarding differences in the cell of origin between ENKL and EBV-harboring PTCL-NOS.
NK-cell receptors found in mature NK cells contribute to positive or negative signaling during NK-cell-mediated cytotoxicity. Activating NKR including DNAM1 (CD226), NKG2D (CD314), and a natural cytotoxicity receptor such as NKp46 (CD335) recognize alterations of cell surface molecules on virus-infected cells and tumor cells. 7 Binding of the activating NKR to ligands induces the activated NK cells to attack their targets. 7 In contrast, inhibitory NKR including CD94-NKG2A and LILRB1 (also known as ILT2/MIR7/CD85j) bind to human leukocyte antigen class I molecules and prevent the NK cells from killing healthy cells. 7 However, the expressions of NKR are shown not only in NK cells, but also in unconventional innatelike T cells comprising cdT cells, invariant NKT cells, mucosal-associated invariant T cells, and intestinal intraepithelial lymphocytes. 8, 9 They play a role in the preservation of tissue integrity and span the innate-adoptive continuum. 8, 9 Previous studies showed that CD94, NKG2A, and NKp46 were usually detected in ENKL, whereas the expression of another group of NKR, the killer cell immunoglobulin-like receptors seem to be reduced in most ENKL cases. [10] [11] [12] The pathological implication of NKR in PTNKL remains to be defined. Therefore, we examined the expressions of LILRB1, DNAM1, NKp46, and NKG2D in several PTNKL entities and carried out a clinicopathological study. 
| MATERIALS AND METHODS

| Case selection and clinical data collection
| Immunohistochemistry
Immunohistochemistry was carried out on sections of FFPE tissues.
In addition to our PTNKL diagnostic panel (the first set: CD3, CD4, CD5, CD8, CM including TIA-1 and GrB, EBER in situ hybridization; the second set: CD30, CD56, PD-1, Bcl-6 and ALK), we assessed the expression profile of TCRb, TCRd, LILRB1, DNAM1, NKp46, and NKG2D, which are available for IHC. Heat-induced antigen retrieval (120°C, 6 min) was carried out using 10 mM citrate buffer, pH 6
(DAKO Japan, Tokyo, Japan). Primary antibodies used were anti- 
| Statistical analysis
Survival curves were determined using the Kaplan-Meier method, and the difference was compared using the log-rank test. All analyses were carried out using EZR (Saitama Medical Center, Jichi Medical University, ver.1.33). 14 All P-values were two-tailed, and P < .05 was considered significant. 
| NKR expression in PTNKL
Representative cases are presented in Figure 1 . A total of 14 cases (64%) were positive for LILRB1 (Table 1) Although there was no significant difference in the OS by age ≥60 years (log-rank test, P = .796), IPI high-risk group (log-rank test, P < .001) had a negative impact on the OS ( Figure 3B ). Expressions of LILRB1 (log-rank test, P = .796), DNAM1 (log-rank test, P = .655), and NKp46 (log-rank test, P = .508) showed no adverse effect on the OS ( Figure 3C-E) , whereas the expression of NKG2D
(log-rank test, P = .024) had a negative impact on the OS (Figure 3F ).
| DISCUSSION
In the present study, we confirmed the expression of LILRB1, DNAM1, NKp46 and NKG2D in some PTNKL entities. Although LILRB1 expression had not yet been evaluated in NK-cell malignancies, we verified the presence in ANKL and ENKL, and further found that the expression pattern was not disease-specific. Previous reports showed that LILRB1 was expressed not only in S ezary cells, but also in B-cell lines. 15, 16 In addition, the stimulation was shown to suppress the proliferation in spite of the different cell lineage. Although several problems such as sensitivity of IHC and loss of expression remain, NKG2D was not so frequently expressed in CMpositive neoplasms. Expression levels of NKG2D in NK cells are likely increased through STAT3 activation, which is considered one of the important alterations in PTNKL. 19, 20 Previous study indicated that approximately 30% of cases of ENKL presented STAT3 phosphorylation. 21 In addition, the activation of STAT3 seems to be associated with a poor clinical outcome in ENKL. 22 Our result may imply that the detection of NKG2D had selected higher risk cases among the patients with relatively poor prognostic diseases such as ANKL, ENKL, and MEITL. Although it is difficult to draw a conclusion as a result of the small numbers of cases, the innate lymphoid cell-associated marker might show an impact on clinical outcome when such standard regimens are adopted.
In summary, we showed, for the first time, that DNAM1 and 
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